Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
78.59
+0.47 (+0.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
...
16
17
18
19
20
21
22
23
24
...
55
56
Next >
AstraZeneca Unusual Options Activity
March 27, 2023
Via
Benzinga
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
March 27, 2023
Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade.
Via
MarketBeat
AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review
March 27, 2023
Via
Benzinga
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks
March 27, 2023
From
AstraZeneca
Via
Business Wire
7 Blue-Chip Stocks to Buy for Capital Preservation
March 23, 2023
These are the low-beta blue-chip stocks to buy as they represent companies with a strong balance sheet and healthy cash flow potential.
Via
InvestorPlace
2 Steady Stocks to Buy and Hold Forever
March 17, 2023
Investing in these companies can help you sleep easy at night.
Via
The Motley Fool
P/E Ratio Insights for AstraZeneca
March 16, 2023
Via
Benzinga
A Look Into AstraZeneca's Debt
March 15, 2023
Via
Benzinga
3 Exceptionally Safe Dividend Stocks That Can Turn $400,000 Into $1 Million by 2030
March 23, 2023
These historically profitable dividend-paying stocks are ideal for risk-averse investors wanting to take advantage of a bear market discount.
Via
The Motley Fool
Nvidia Ramps Up Artificial Intelligence Offerings Amid AI's 'iPhone Moment'
March 21, 2023
Nvidia on Tuesday demonstrated how its technology is advancing artificial intelligence in myriad industries. Nvidia stock has soared in 2023.
Via
Investor's Business Daily
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information
March 21, 2023
Via
Benzinga
GSK's Chief Scientist Says R&D Focus More On Infectious Disease, HIV Amid Patent Expiration, Dwindling Sales
March 15, 2023
GSK Plc's (NYSE: GSK) top scientist, Tony Wood, who took the helm of R&D last August, says the R&D department is now delivering results. Wood said he is de-emphasizing R&D in oncology and that the R&D...
Via
Benzinga
AstraZeneca's Debt Overview
March 02, 2023
Shares of AstraZeneca Inc. (NASDAQ:AZN) fell by 5.41% in the past three months. Before having a look at the importance of debt, let's look at how much debt AstraZeneca has.
Via
Benzinga
Rise in Biotech Innovations Generating Hope as Pancreatic Cancer Survival Rates Climb
March 14, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2023 – USA News Group – Optimism is on the rise as the American Cancer Society is reporting that the five-year survival...
Via
FinancialNewsMedia
Exposures
Product Safety
AstraZenceca's Tagrisso Shows Survival Benefit In Early-Stage Lung Cancer Settings
March 09, 2023
Via
Benzinga
AstraZeneca's Immunotherapy Imfinzi Shows Improvement In Survival Chances In Lung Cancer Patients
March 09, 2023
Via
Benzinga
TAGRISSO® (osimertinib) demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
March 09, 2023
From
AstraZeneca
Via
Business Wire
IMFINZI significantly improved event-free survival in AEGEAN Phase III trial for patients with resectable non-small cell lung cancer
March 09, 2023
From
AstraZeneca
Via
Business Wire
Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race
March 08, 2023
These companies aren't working on a vaccine, but a monoclonal antibody.
Via
Investor's Business Daily
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
March 08, 2023
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
3 No-Brainer Stocks to Buy With $400 Right Now
March 08, 2023
A reasonably small amount of money can go a long way when it's invested in innovative businesses.
Via
The Motley Fool
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
March 06, 2023
Via
Benzinga
4 AI Stocks That Are Revolutionizing Healthcare
March 06, 2023
With the growing use of AI in healthcare, it has led to a number of stocks that are focused on this industry.
Via
InvestorPlace
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Showed Clinically Meaningful and Durable Responses Across Multiple HER2-expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial
March 06, 2023
From
AstraZeneca
Via
Business Wire
Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023
March 02, 2023
From
AstraZeneca
Via
Business Wire
Valneva Shares Updated Data From Now Shelved COVID-19 Vaccine Development Program
March 02, 2023
Via
Benzinga
Why Emergent BioSolutions Stock Tumbled by Almost 12% Today
February 28, 2023
It's not a good day for investors when their company reports a shocking plunge into the red.
Via
The Motley Fool
Why Compugen Shares Are Up Today
February 28, 2023
The company released its fourth-quarter and full-year results after the bell Monday.
Via
The Motley Fool
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
February 25, 2023
Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between...
Via
Talk Markets
Analysts Holding As Pfizer Waits On Two Phase 3 Studies
February 24, 2023
Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value.
Via
MarketBeat
Topics
Bankruptcy
Exposures
Financial
Legal
< Previous
1
2
...
16
17
18
19
20
21
22
23
24
...
55
56
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.